GO:0050677 positive regulation of urothelial cell proliferation: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050677 describes any process that activates or increases the rate or extent of urothelial cell proliferation, a key biological process in bladder tissue homeostasis and cancer.
• Dysregulation of this process is a hallmark of urothelial carcinoma, where enhanced proliferation drives tumor growth and progression.
• Key molecular players include SPOP, PTEN, NACC1, and REG4, which modulate proliferation through STAT3, PI3K/AKT, and other signaling axes.
• Experimental models such as CRISPR knockout, point mutation, and overexpression in urothelial cell lines are essential to dissect causal roles of specific genes.
• Understanding positive regulation of urothelial cell proliferation informs targeted therapies and biomarker discovery for bladder cancer.
• EDITGENE provides comprehensive CRISPR services to study this process, from library screening to custom cell model generation.
Description
Urothelial cell proliferation is a fundamental biological process required for the maintenance and regeneration of the urothelium, the specialized epithelium lining the urinary tract. The Gene Ontology term GO:0050677, positive regulation of urothelial cell proliferation, encompasses any molecular event that stimulates or enhances the rate or extent of this proliferation. This process is tightly controlled under normal conditions but becomes aberrantly activated in urothelial carcinoma, where uncontrolled proliferation contributes to tumor initiation, progression, and metastasis. Understanding the positive regulators of urothelial cell proliferation is therefore critical for elucidating bladder cancer pathogenesis and identifying therapeutic targets. Recent studies have highlighted diverse signaling pathways and regulatory proteins, including SPOP, PTEN, NACC1, and REG4, that modulate this process. The heterogeneity of urothelial cancer subtypes further underscores the need to study context-specific regulators. This article synthesizes current knowledge on GO:0050677, covering its definition, mechanisms, key genes, disease relevance, and research methodologies, with a focus on CRISPR-based approaches for functional validation.
positive regulation of urothelial cell proliferation At A Glance
| GO ID | GO:0050677 |
|---|---|
| GO term | positive regulation of urothelial cell proliferation |
| Ontology | biological_process |
| Definition | Any process that activates or increases the rate or extent of urothelial cell proliferation. |
| Synonyms | activation of urothelial cell proliferation, stimulation of urothelial cell proliferation, up regulation of urothelial cell proliferation, up-regulation of urothelial cell proliferation, upregulation of urothelial cell proliferation |
| Major function | Promotes the division and expansion of urothelial cells, critical for tissue homeostasis and implicated in bladder cancer. |
| Related processes | Cell cycle progression, growth factor signaling, oncogenic transformation. |
| Disease relevance | Urothelial carcinoma, bladder cancer progression. |
What Is GO:0050677?
GO:0050677, positive regulation of urothelial cell proliferation, is defined by the Gene Ontology as any process that activates or increases the rate or extent of urothelial cell proliferation. In other words, it includes all molecular signals, pathways, and cellular events that promote the division and expansion of urothelial cells, which line the urinary bladder and other parts of the urinary tract. This term is a child of 'positive regulation of cell proliferation' and is specific to the urothelial cell type. It is used to annotate gene products that experimentally enhance urothelial cell proliferation, such as growth factors, oncogenes, or signaling molecules.
Why Is positive regulation of urothelial cell proliferation Important in Cell Biology?
Positive regulation of urothelial cell proliferation is critically important because it governs the regenerative capacity of the urothelium and, when dysregulated, drives urothelial carcinoma, one of the most common malignancies of the urinary tract. Understanding the molecular mechanisms that positively regulate this process can reveal actionable targets for cancer therapy and provide insights into normal tissue repair. Moreover, the heterogeneity of urothelial cancers means that different molecular subtypes may rely on distinct proliferative signals, necessitating a detailed map of the regulators. Research into GO:0050677 also intersects with developmental biology and regenerative medicine, as controlled urothelial proliferation is essential for bladder tissue engineering and repair.
• Drives tumor growth and progression in urothelial carcinoma, making it a central focus of bladder cancer research.
• Influences response to therapies, including chemotherapy and targeted agents like enfortumab vedotin.
• Modulates the tumor immune microenvironment through crosstalk between cancer cells and macrophages.
• Involves epigenetic regulation, such as DNA methylation of tumor suppressor genes like WIF1 and GSTM5.
• Serves as a model for studying cell cycle control and oncogenic signaling in epithelial cancers.
• Provides potential biomarkers for prognosis and treatment stratification in bladder cancer.
• Underpins normal urothelial regeneration, relevant to tissue engineering and repair.
• Offers targets for CRISPR-based functional genomics to identify novel regulators.
• Connects to pan-cancer proliferation mechanisms, as seen with CD73 and REG4.
• Facilitates drug discovery through high-throughput screening of proliferation modulators.
What Happens During positive regulation of urothelial cell proliferation?
Initiation by Growth Factors and Oncogenic Signals
In simple terms: Growth factors and oncogenes act like keys that start the engine of cell division in urothelial cells.
Positive regulation of urothelial cell proliferation begins with extracellular signals, such as growth factors, cytokines, and hormones, that bind to cell surface receptors and activate intracellular signaling cascades. Oncogenic mutations or overexpression of signaling molecules can constitutively activate these pathways. For example, SPOP downregulation in bladder cancer promotes proliferation through the STAT3/CCL2/IL-6 axis, involving crosstalk with macrophages. Similarly, REG4 has been shown to promote proliferation and anti-apoptosis in cancer cells. These initiating events trigger downstream effectors that drive cell cycle entry.
Signal Transduction and Key Pathways
In simple terms: Inside the cell, a relay race of proteins carries the growth signal to the nucleus, telling the cell to divide.
Upon receptor activation, intracellular signaling pathways such as PI3K/AKT, MAPK/ERK, and JAK/STAT are engaged. PTEN, a tumor suppressor, negatively regulates the PI3K/AKT pathway; its degradation by SNHG1 leads to enhanced proliferation in basal muscle invasive bladder cancer. NACC1, regulated by microRNA-331-3p, also controls proliferation in urothelial carcinoma cells. These pathways converge on transcription factors that promote expression of cell cycle genes.
Cell Cycle Progression and DNA Replication
In simple terms: The cell commits to division by passing through checkpoints and copying its DNA.
Activated signaling leads to the expression of cyclins and cyclin-dependent kinases (CDKs), which drive progression through the G1/S checkpoint and subsequent phases of the cell cycle. DNA replication occurs, and the cell prepares for mitosis. Positive regulators of urothelial proliferation often upregulate cyclin D1, c-Myc, and other proliferation-associated genes. The net effect is an increased rate of cell division, expanding the urothelial cell population.
Crosstalk with Tumor Microenvironment
In simple terms: Cancer cells talk to nearby immune cells, which can send back signals that further boost proliferation.
In the context of cancer, positive regulation of urothelial cell proliferation is not cell-autonomous. SPOP downregulation in bladder cancer cells promotes macrophage recruitment and M2 polarization via the STAT3/CCL2/IL-6 axis, which in turn feeds back to enhance tumor cell proliferation. This crosstalk highlights the importance of the tumor microenvironment in sustaining proliferative signals.
Epigenetic and Post-Translational Modulation
In simple terms: Chemical tags on DNA and proteins can dial the proliferation signal up or down.
Epigenetic mechanisms, such as DNA methylation, regulate the expression of genes involved in urothelial proliferation. For instance, promoter methylation of WIF1 and GSTM5 is observed in urothelial carcinoma, potentially affecting Wnt signaling and oxidative stress responses that influence proliferation. Post-translational modifications, including ubiquitination and phosphorylation, control the stability and activity of key regulators like PTEN and SPOP.
Key Genes Involved in GO:0050677 positive regulation of urothelial cell proliferation
The following genes and proteins have been experimentally implicated in the positive regulation of urothelial cell proliferation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SPOP | Downregulation promotes proliferation via STAT3/CCL2/IL-6 axis and macrophage crosstalk | Therapeutic target in bladder cancer; regulates tumor microenvironment |
| NECTIN4 | Cell adhesion molecule; expression heterogeneity affects sensitivity to enfortumab vedotin | Biomarker for targeted therapy in urothelial cancer |
| REG4 | Promotes proliferation and anti-apoptosis in cancer cells | Potential oncogene; studied in gastrointestinal and other cancers |
| CD73 | Ectoenzyme involved in immune suppression and proliferation | Pan-cancer prognostic marker; linked to tumor immune microenvironment |
| PTEN | Tumor suppressor; degradation by SNHG1 enhances proliferation | Frequently altered in bladder cancer; regulates PI3K/AKT |
| WIF1 | Wnt signaling inhibitor; epigenetic silencing may promote proliferation | Methylation biomarker in urothelial carcinoma |
| GSTM5 | Glutathione S-transferase; involved in detoxification; methylation observed in urothelial carcinoma | Potential tumor suppressor; epigenetic regulation |
| UCA1 | Long noncoding RNA; silence inhibits proliferation and chemotherapy resistance | Oncogenic lncRNA in gastric cancer; may have pan-cancer roles |
| NACC1 | Regulates cell proliferation; target of miR-331-3p | Oncogene in urothelial carcinoma; potential therapeutic target |
| STAT3 | Transcription factor downstream of SPOP; drives CCL2/IL-6 expression | Central signaling node in bladder cancer proliferation |
| CCL2 | Chemokine mediating macrophage recruitment | Tumor microenvironment modulator |
| IL-6 | Cytokine promoting proliferation and inflammation | Therapeutic target in bladder cancer |
| SNHG1 | Long noncoding RNA; upregulation leads to PTEN degradation | Oncogenic lncRNA in basal muscle invasive bladder cancer |
| miR-331-3p | MicroRNA targeting NACC1 | Tumor suppressor miRNA; regulates proliferation |
| PI3K/AKT | Signaling pathway promoting proliferation | Frequently activated in urothelial carcinoma |
| Wnt/β-catenin | Signaling pathway regulating proliferation | Modulated by WIF1; target for therapy |
| Cyclin D1 | Cell cycle regulator | Downstream effector of proliferative signals |
| c-Myc | Transcription factor promoting proliferation | Oncogene often overexpressed in bladder cancer |
How Is positive regulation of urothelial cell proliferation Regulated?
The positive regulation of urothelial cell proliferation is controlled at multiple levels. Signaling pathways such as PI3K/AKT, JAK/STAT, and Wnt/β-catenin are subject to negative feedback and crosstalk. Tumor suppressors like PTEN and WIF1 act as brakes; their loss or epigenetic silencing unleashes proliferation. MicroRNAs, such as miR-331-3p, can downregulate oncoproteins like NACC1. Additionally, long noncoding RNAs like SNHG1 and UCA1 modulate proliferation by interacting with proteins or miRNAs. The tumor microenvironment, through cytokines like IL-6 and chemokines like CCL2, provides external stimuli that sustain proliferative signaling. Understanding these regulatory layers is essential for developing targeted interventions.
positive regulation of urothelial cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SPOP | Bladder cancer progression, macrophage crosstalk | Knockout or knockdown in urothelial cell lines; co-culture with macrophages |
| PTEN | Basal muscle invasive bladder cancer | CRISPR knockout in bladder cancer cell lines; xenograft models |
| NACC1 | Urothelial carcinoma proliferation | Overexpression and knockout in urothelial carcinoma cells; miRNA mimic/inhibitor |
| NECTIN4 | Urothelial cancer sensitivity to enfortumab vedotin | Knockout and overexpression in patient-derived models; drug sensitivity assays |
| CD73 | Pan-cancer prognosis and immune microenvironment | Knockout in cancer cell lines; immune cell co-culture |
Urothelial Carcinoma and Bladder Cancer
Dysregulated positive regulation of urothelial cell proliferation is a hallmark of urothelial carcinoma, the most common type of bladder cancer. Enhanced proliferation drives tumor growth, invasion, and metastasis. Key molecular alterations include SPOP downregulation, PTEN degradation, and NACC1 overexpression, all of which promote proliferative signaling. The heterogeneity of urothelial cancer subtypes, as seen with NECTIN4 expression, influences sensitivity to therapies like enfortumab vedotin. Epigenetic changes, such as WIF1 and GSTM5 methylation, further contribute to uncontrolled proliferation. Targeting these pathways is a major therapeutic strategy.
Pan-Cancer Relevance and Immune Microenvironment
While GO:0050677 is specific to urothelial cells, the underlying mechanisms often overlap with other cancers. For example, CD73 is a pan-cancer marker associated with prognosis and tumor immune microenvironment, influencing proliferation and immune evasion. REG4 promotes proliferation and anti-apoptosis in various cancer types. UCA1, a long noncoding RNA, inhibits malignant proliferation and chemotherapy resistance in gastric cancer, suggesting broader roles in proliferation regulation. These findings highlight the interconnectedness of proliferative pathways across cancer types.
Therapeutic Implications and Resistance
Positive regulation of urothelial cell proliferation directly impacts response to chemotherapy and targeted agents. For instance, NECTIN4 heterogeneity mediates sensitivity to enfortumab vedotin, an antibody-drug conjugate. SPOP downregulation promotes a tumor-promoting microenvironment that may confer resistance. Understanding the specific proliferative drivers in individual tumors can guide precision medicine approaches, including combination therapies that block multiple proliferative signals.
From positive regulation of urothelial cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X promote urothelial cell proliferation? | CRISPR knockout in urothelial cell lines (e.g., T24, RT4) followed by proliferation assays |
| Does a specific point mutation in gene Y alter proliferative capacity? | CRISPR point mutation knock-in in urothelial cells; compare with wild-type |
| Does overexpression of gene Z drive proliferation? | CRISPR-mediated overexpression (e.g., CRISPRa) or lentiviral overexpression in urothelial cells |
| What is the role of gene W in tumor microenvironment crosstalk? | Knockout in cancer cells co-cultured with macrophages; cytokine profiling |
| Can a tagged knock-in of gene V reveal its localization during proliferation? | CRISPR knock-in of fluorescent or epitope tag; imaging and co-IP |
| Which genes are essential for urothelial proliferation? | Genome-wide CRISPR library screening in urothelial cell lines |
How to Study the positive regulation of urothelial cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on proliferation | Identify essential genes for urothelial proliferation |
| EdU/BrdU incorporation | DNA synthesis (S-phase entry) | Quantify proliferation rate in vitro |
| RNA-seq | Transcriptome changes | Discover pathways altered by gene manipulation |
| Phosphoproteomics | Kinase activity and signaling | Map signaling cascades driving proliferation |
| Co-culture assays | Cell-cell interactions | Study tumor-macrophage crosstalk |
| Xenograft models | Tumor growth in vivo | Validate proliferative drivers and drug responses |
| Immunohistochemistry | Protein expression and localization in tissues | Assess proliferation markers (Ki-67) in patient samples |
| Flow cytometry | Cell cycle distribution | Analyze cell cycle progression after gene editing |
CRISPR-Based Functional Genomics
CRISPR knockout, activation, and interference screens enable systematic identification of genes that positively regulate urothelial cell proliferation. Pooled library screening coupled with next-generation sequencing can uncover novel regulators and pathways. For example, genome-wide screens in urothelial carcinoma cells can reveal dependencies on specific oncogenes or tumor suppressors.
Proliferation Assays
Standard methods to measure urothelial cell proliferation include MTT, BrdU, EdU incorporation, and colony formation assays. These assays quantify DNA synthesis and cell division, providing direct readouts of proliferative capacity. They are often used to validate hits from CRISPR screens or to assess the effects of gene knockdown or overexpression.
Molecular Profiling
RNA sequencing (RNA-seq) and proteomics can reveal global changes in gene expression and protein abundance upon modulation of positive regulators. Phosphoproteomics can identify signaling pathways activated during proliferation. These approaches help construct the regulatory network underlying GO:0050677.
In Vivo Models
Xenograft and orthotopic bladder cancer models in mice allow assessment of tumor growth and proliferation in a physiological context. CRISPR-engineered cells can be implanted to study the role of specific genes in tumor progression. These models also enable evaluation of therapeutic interventions targeting proliferative pathways.
How CRISPR Can Be Used to Study GO:0050677 positive regulation of urothelial cell proliferation
Knockout
CRISPR knockout is used to delete genes suspected of positively regulating urothelial cell proliferation. By introducing frameshift mutations, researchers can assess loss-of-function effects on proliferation, signaling, and tumor growth. For example, knocking out SPOP or PTEN in urothelial cells can reveal their roles in proliferation and crosstalk with the microenvironment.
Point Mutation
CRISPR point mutation allows precise introduction of specific nucleotide changes to model oncogenic or tumor suppressor mutations. This is valuable for studying how missense mutations in genes like PTEN or NACC1 affect proliferative capacity and downstream signaling. Point mutation knock-in can also create drug-resistant alleles for mechanistic studies.
Knock-in
CRISPR knock-in enables insertion of reporter tags (e.g., GFP, luciferase) or epitope tags into endogenous loci. This allows real-time tracking of protein expression, localization, and interactions during urothelial cell proliferation. Tagged knock-in models are useful for imaging and proteomic studies.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression is used to increase expression of candidate genes to test whether they are sufficient to drive urothelial cell proliferation. Overexpression of REG4 or NACC1, for instance, can promote proliferation and anti-apoptosis, validating their oncogenic potential.
How EDITGENE Supports positive regulation of urothelial cell proliferation Research
Researchers studying positive regulation of urothelial cell proliferation-related genes often need to determine whether a candidate gene is causally involved in driving or sustaining proliferation. EDITGENE provides end-to-end CRISPR solutions to generate precisely engineered urothelial cell models, enabling functional validation and mechanistic dissection of GO:0050677.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of urothelial cell proliferation research.
Frequently Asked Questions About positive regulation of urothelial cell proliferation
What is GO:0050677?
GO:0050677 is the Gene Ontology term for positive regulation of urothelial cell proliferation, defined as any process that activates or increases the rate or extent of urothelial cell proliferation.
What genes are involved in positive regulation of urothelial cell proliferation?
Key genes include SPOP, PTEN, NACC1, REG4, NECTIN4, CD73, WIF1, GSTM5, UCA1, and SNHG1, among others.
How is urothelial cell proliferation regulated?
It is regulated by growth factor signaling, oncogenic pathways (e.g., PI3K/AKT, JAK/STAT), tumor suppressors, microRNAs, long noncoding RNAs, and epigenetic modifications.
Why is positive regulation of urothelial cell proliferation important in cancer?
Dysregulation leads to uncontrolled growth in urothelial carcinoma, driving tumor progression and resistance to therapy.
What experimental models are used to study GO:0050677?
CRISPR knockout, point mutation, knock-in, overexpression in urothelial cell lines, and xenograft models are commonly used.
How can CRISPR help study urothelial cell proliferation?
CRISPR enables precise gene editing to test loss-of-function, gain-of-function, and specific mutations, revealing causal roles in proliferation.
What is the role of SPOP in urothelial cell proliferation?
SPOP downregulation promotes bladder cancer progression via STAT3/CCL2/IL-6 axis and macrophage crosstalk, enhancing proliferation.
How does PTEN affect urothelial cell proliferation?
PTEN degradation by SNHG1 leads to increased proliferation in basal muscle invasive bladder cancer.
What is NACC1's function in urothelial carcinoma?
NACC1, targeted by miR-331-3p, regulates cell proliferation in urothelial carcinoma cells.
What services does EDITGENE offer for studying this process?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study urothelial cell proliferation.
Conclusion
Positive regulation of urothelial cell proliferation (GO:0050677) is a central biological process in both normal urothelial homeostasis and bladder cancer pathogenesis. The interplay of oncogenes, tumor suppressors, noncoding RNAs, and the tumor microenvironment creates a complex regulatory network that is increasingly well understood through CRISPR-based functional studies. Targeting these pathways holds promise for novel therapies. EDITGENE's comprehensive CRISPR services empower researchers to dissect these mechanisms and accelerate translational discoveries.
References
- 1. Li M et al.. 2024. SPOP downregulation promotes bladder cancer progression based on cancer cell-macrophage crosstalk via STAT3/CCL2/IL-6 axis and is regulated by VEZF1.. Theranostics 14(17):6543-6559 PMID: 39479456
- 2. Chu CE et al.. 2021. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.. Clin Cancer Res 27(18):5123-5130 PMID: 34108177
- 3. Zheng HC et al.. 2022. REG4 promotes the proliferation and anti-apoptosis of cancer.. Front Cell Dev Biol 10:1012193 PMID: 36172286
- 4. Chen C et al.. 2024. Comprehensive pan-cancer analysis of CD73: Explore its association with prognosis and tumor immune microenvironment.. Heliyon 10(22):e40329 PMID: 39624281
- 5. Li T et al.. 2024. Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation.. J Exp Clin Cancer Res 43(1):50 PMID: 38365726
- 6. Shen CH et al.. 2023. Epigenetic regulation of human WIF1 and DNA methylation situation of WIF1 and GSTM5 in urothelial carcinoma.. Heliyon 9(5):e16004 PMID: 37206019
- 7. Shang C et al.. 2016. Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer.. Cancer Chemother Pharmacol 77(5):1061-7 PMID: 27056384
- 8. Morita K et al.. 2018. NACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells.. Cancers (Basel) 10(10) PMID: 30248959
